<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975767</url>
  </required_header>
  <id_info>
    <org_study_id>265-103</org_study_id>
    <nct_id>NCT00975767</nct_id>
  </id_info>
  <brief_title>A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the safety profile of MGCD265 when administered
      in combination with the marketed anticancer drugs erlotinib and docetaxel.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to a need for a reformulation of the study drug. Phase 1
    completed, no patients enrolled in Phase 2.
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Safety profile (including maximum tolerated dose and dose limiting toxicities)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Antitumor activity of MGCD265+erlotinib and MGCD265+docetaxel</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Pharmacokinetic profiles of MGCD265+erlotinib and MGCD265+docetaxel</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: Pharmacodynamic profiles of MGCD265+erlotinib and MGCD265+docetaxel</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Antitumor activity of MGCD265+erlotinib and MGCD265+docetaxel.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Safety profile of MGCD265+erlotinib and MGCD265+docetaxel;</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Advanced Malignancies, Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>MGCD265+erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MGCD265+docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGCD265+erlotinib</intervention_name>
    <description>MGCD265 and erlotinib administered daily</description>
    <arm_group_label>MGCD265+erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGCD265+docetaxel</intervention_name>
    <description>MGCD265 administered daily; docetaxel administered once every 3 weeks</description>
    <arm_group_label>MGCD265+docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1:

               -  Patients with advanced metastatic or unresectable solid malignancy that is
                  refractory to standard therapy and/or existing therapies.

               -  Evaluable disease.

               -  Documented progressive disease during or following most recent treatment regimen.

               -  Adequate hepatic parameters.

               -  Age ≥18 years.

               -  Life expectancy greater than 3 months.

               -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

               -  Adequate renal function.

               -  Adequate bone marrow function.

               -  Capable of understanding and complying with the protocol and written informed
                  consent.

               -  Negative pregnancy test for women of childbearing potential.

               -  Use of adequate contraception as needed.

               -  Subjects consenting to optional fresh biopsies, must not require concurrent
                  anticoagulation medication.

          -  Part 2:

               -  Histologically or cytologically confirmed advanced Stage 3b or 4 NSCLC.

               -  Measurable disease per RECIST.

               -  At least one prior chemotherapy regimen for advanced disease.

               -  No prior erlotinib or docetaxel therapy.

               -  Documented progressive disease during or following most recent treatment regimen.

               -  Adequate hepatic parameters.

               -  Age ≥18 years.

               -  Life expectancy greater than 3 months.

               -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

               -  Adequate renal function.

               -  Adequate bone marrow function.

               -  Capable of understanding and complying with the protocol and written informed
                  consent.

               -  Negative pregnancy test for women of childbearing potential.

               -  Use of adequate contraception as needed.

        Exclusion Criteria:

          -  Recent anticancer treatment.

          -  Prior treatment with an investigational cmet inhibitor or HCF inhibitor or antibody.

          -  Uncontrolled concurrent illness.

          -  History of bleeding diathesis or coagulopathy.

          -  History of stroke or transient ischemic attack.

          -  History of a cardiovascular illness.

          -  QT interval corrected for heart rate (QTc) &gt;470 msec.

          -  Left ventricular ejection fraction (LVEF) &lt;50%.

          -  Immunocompromised subjects.

          -  Lack of recovery to grade ≤1 from significant adverse events due to antineoplastic
             agents, investigational drugs, or other medications administered prior to study
             enrollment.

          -  Symptomatic or uncontrolled brain metastases requiring current treatment.

          -  Active gastrointestinal conditions or a history of abdominal fistula, gastrointestinal
             perforation or intra-abdominal abscess.

          -  History of other malignancy treated with curative intent within the 5 previous years.

          -  Lung tumor lesions with increased likelihood of bleeding.

          -  History of major surgery within 28 days of first receipt of study drug.

          -  History of autologous bone marrow transplant (BMT) within the previous five years, or
             subjects with organ transplants or allogeneic BMT.

          -  Nursing or pregnant women; female subjects of childbearing potential must have a
             negative pregnancy test at screening.

          -  Unable to swallow oral medications or with pre-existing gastrointestinal disorders
             that might interfere with proper absorption of oral drugs.

          -  Any other condition or finding that in the opinion of the Investigator or Medical
             Monitor may render the subject at excessive risk for treatment complications or may
             render difficult the evaluation of treatment response.

          -  Allergy or hypersensitivity to components of either the MGCD265, erlotinib or
             docetaxel formulations (depending on the group that the subject is assigned to).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Tassell</last_name>
    <role>Study Director</role>
    <affiliation>MethylGene Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

